Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10682128 | 0.88 | DGAT1 (0.35) | TSHRALDH1A1CA1CA2MAPK1 | |
| SCHEMBL30805232 | 0.84 | CYP4A11 (0.41) | TSHR | |
| SCHEMBL9450186 | 0.84 | TSHR (0.40) | TSHRCES2CES1ALDH1A1ATM | |
| SCHEMBL16869115 | 0.82 | ALDH1A1 (0.44) | TSHRCES2CES1ALDH1A1PLA2G2C | |
| SCHEMBL16174064 | 0.82 | CYP3A4 (0.57) | TSHRCYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL13391772 | 0.82 | ALDH1A1 (0.43) | TSHRALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL27959697 | 0.81 | ALDH1A1 (0.45) | TSHRCES2CES1ALDH1A1ATM | |
| SCHEMBL20730298 | 0.81 | CYP4F2 (0.46) | CES2CES1MAPTACHE | |
| SCHEMBL17574066 | 0.80 | DGAT1 (0.42) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL5852063 | 0.79 | TSHR (0.43) | TSHRCES2CES1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-8372859-B2 | CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups | Merck, Sharp & Dohme Corp. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20100292263-A1 | CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMITE AND UREA GROUPS | MERCK SHARP & DOHME LLC | 2010-11-18 | — | — | US | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2008127584-A1 | CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMATE AND UREA END GROUPS | MERCK & CO., INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | TSHR 3963/4885CES2 4225/4885CES1 2413/4885 |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | TSHR 1996/4885CES2 2365/4885CES1 1744/4885 |
| US-20100292263-A1 | CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMITE AND UREA GROUPS | CALCR, QRFPR, CALCRL | TSHR 199/4885CES2 1202/4885CES1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.